ADPT News and Press, Adaptive Biotechnologies Corporation From 02/25/24

2024-02-25 10:40:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the fourth quarter of 2023, Aristo...

2024-02-25 10:20:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the fourth quarter of 2023, Aristo...

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating...

2024-02-14 21:51:03 ET Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Conference Call February 14, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Susan Bobulsky - Senior Vi...

2024-02-14 16:21:46 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: MRD Success In A Challenging Market Adaptive Biotechnologies Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Adaptive Biotechnologies Historical earnings data fo...

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat diseas...

Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...

2024-02-13 17:20:51 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: MRD Success In A Challenging Market Seeking Alpha’s Quant Rating on Adaptive Biotechnologies Historical earnings data for Adaptive Biotechnologies Financial information f...

SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial...

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating...